
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Bethesda, MD-A combination of low-dose bacille Calmette-Guin and interferon-alpha (IFN-a) has shown promise in the treatment of bladder cancer patients who have failed initial treatment with BCG.





